Table 3
Clinical characteristics of patients who developed dry eye after SCT
| No | Sex | Age (years) | Diagnosis | Donor | Onset (day) | Dry eye | GVHD | Complaints (points) | F (points) | RB (points) | BUT (seconds) | Schirmer (mm) | NST (mm) | MGD score (points) | |||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| pre | post | pre | post | pre | post | pre | post | pre | post | pre | post | ||||||||||||||||||||||||||||
| 1 | M | 45 | MDS | related | 83 | mild | a | c | 0 | 3 | 3 | 1 | 0 | 1 | 10 | 5 | 5 | 2 | 30 | 0 | |||||||||||||||||||
| 2 | M | 36 | CML | related | 180 | mild | a | c | 22 | 0 | 3 | 0 | 2 | 10 | 5 | 19 | 14 | 26 | 23 | 0 | |||||||||||||||||||
| 3 | M | 42 | ALL | related | 90 | mild | no | no | 0 | 10 | 1 | 0 | 0 | 1 | 10 | 5 | 8 | 4 | 10 | 16 | 0 | ||||||||||||||||||
| 4 | M | 41 | AML | related | 150 | mild | a | c | 11 | 11 | 1 | 2 | 0 | 4 | 10 | 2 | 4 | 8 | 34 | 15 | 2 | ||||||||||||||||||
| 5 | F | 46 | ALL | unrelated | 90 | mild | no | no | 6 | 26 | 0 | 3 | 0 | 2 | 10 | 1 | 22 | 0 | 34 | 17 | 0 | ||||||||||||||||||
| 6 | F | 44 | MDS, AML | unrelated | 150 | mild | no | c | 2 | 0 | 1 | 0 | 1 | 10 | 10 | 8 | 3 | 9 | 1 | ||||||||||||||||||||
| 7 | M | 40 | AML | unrelated | 240 | mild | a | c | 3 | 7 | 0 | 4 | 0 | 4 | 10 | 5 | 11 | 8 | 15 | 33 | 1 | ||||||||||||||||||
| 8 | M | 24 | AML | related | 150 | mild | a | c | 1 | 1 | 1 | 3 | 1 | 3 | 10 | 10 | 11 | 1 | 22 | 14 | 0 | ||||||||||||||||||
| 9 | M | 43 | MM | related | 90 | mild | a | c | 1 | 4 | 0 | 3 | 0 | 3 | 10 | 4 | 16 | 6 | 33 | 17 | 1 | ||||||||||||||||||
| 10 | F | 44 | CML | related | 240 | mild | a | c | 0 | 10 | 0 | 1 | 0 | 1 | 8 | 10 | 6 | 3 | 8 | 8 | 0 | ||||||||||||||||||
| 11 | M | 30 | ALL | unrelated | 90 | mild | no | no | 0 | 4 | 0 | 2 | 0 | 2 | 10 | 5 | 27 | 18 | 14 | 20 | 1 | ||||||||||||||||||
| 12 | M | 37 | CML | unrelated | 240 | mild | a | c | 2 | 2 | 0 | 6 | 0 | 2 | 10 | 10 | 28 | 22 | 13 | 16 | 2 | ||||||||||||||||||
| 13 | F | 30 | AML | related | 510 | severe | a | c | 0 | 12 | 0 | 1 | 0 | 3 | 10 | 5 | 5 | 3 | 12 | 5 | 1 | ||||||||||||||||||
| 14 | F | 21 | AML | unrelated | 180 | severe | a | c | 4 | 30 | 2 | 7 | 0 | 7 | 10 | 2 | 13 | 4 | 26 | 1 | 2 | ||||||||||||||||||
| 15 | F | 25 | ALL | related | 109 | severe | a | c | 2 | 8 | 0 | 3 | 0 | 4 | 10 | 5 | 4 | 6 | 3 | 5 | 1 | ||||||||||||||||||
| 16 | M | 33 | AML | unrelated | 180 | severe | no | c | 0 | 8 | 1 | 5 | 0 | 5 | 10 | 8 | 35 | 6 | 34 | 6 | 2 | ||||||||||||||||||
| 17 | M | 29 | CML | related | 168 | severe | no | c | 0 | 9 | 0 | 6 | 0 | 7 | 10 | 2 | 32 | 4 | 35 | 4 | 2 | ||||||||||||||||||
| 18 | F | 22 | ALL | related | 120 | severe | a | c | 0 | 38 | 0 | 6 | 0 | 5 | 10 | 3 | 12 | 2 | 27 | 3 | 2 | ||||||||||||||||||
| 19 | F | 43 | MDS | unrelated | 150 | severe | a | c | 9 | 16 | 1 | 4 | 3 | 3 | 8 | 2 | 1 | 0 | 4 | 1 | 2 | ||||||||||||||||||
| 20 | M | 35 | MM | related | 210 | severe | a | c | 0 | 18 | 0 | 5 | 0 | 3 | 10 | 8 | 12 | 3 | 29 | 7 | 2 | ||||||||||||||||||
| 21 | M | 43 | MDS | unrelated | 135 | severe | a | c | 0 | 9 | 0 | 2 | 0 | 1 | 10 | 2 | 9 | 3 | 15 | 9 | 2 | ||||||||||||||||||
| 22 | F | 35 | CML | unrelated | 200 | severe | a | c | 15 | 32 | 2 | 6 | 2 | 5 | 9 | 2 | 4 | 0 | 3 | 0 | 2 | ||||||||||||||||||
-
SCT = stem cell transplantaion; GVHD = GVHD in organs other than the eyes; F = fluorescein score; RB = rose bengal score; BUT = tear break up time; NST = Schirmer test with nasal stimulation; MGD = meibomian gland dysfunction; pre = pre-SCT; post = post-SCT; a = acute; c = chronic; MDS =myelodysplastic syndrome; CML = chronic myeloid leukaemia; ALL = acute lymphoblastic leukaemia; AML = acute myeloid leukaemia; MM = multiple myeloma.
